PRESS RELEASE

The Board of Directors examined the consolidated sales as of September 30, 2026, which show a further acceleration of growth in the third quarter

- **Consolidated Net Sales: € 1,447.4 million**
  (+10.4% compared to € 1,311.6 million as of 09/30/2025)
- **Technical Gases segment sales: € 714.1 million**
  (+7.7% compared to € 663.1 million as of 09/30/2025)
- **Home Medical Care segment sales: € 764.3 million**
  (+12.6% compared to € 678.9 million as of 09/30/2025)

The Board of Directors of SOL S.p.A., the holding company of a multinational Group with over 8,300 employees active in the technical and medical gases and home care sectors, met today to examine the sales trend of the SOL Group from January to September 2026.

The first nine months of 2026 unfolded against a still complex global macroeconomic environment characterized by persistent volatility. Despite a general resilience in economic activity levels, the continuation of international geopolitical tensions – particularly in the Middle East and Ukraine – continues to affect raw material and energy product costs, triggering renewed inflationary pressures. This dynamic prompted a renewed tightening of monetary policies, with interest rates rising across major central banks, within a system experiencing growth at varying speeds across different geographical areas.

Analysis of Group sales

In this challenging economic scenario, the first nine months of 2026 closed with **consolidated sales of € 1,447.4 million,** recording a positive change of **+10.4%** compared to the corresponding period of the previous year (€ 1,311.6 million), of which -0.2 pp from exchange rate effects and +1.9 pp from changes in the scope of consolidation.

In the third quarter of 2026 alone, Group sales reached **€ 498.9 million**, highlighting an acceleration with an increase of **+14.0%** compared to € 437.6 million in the third quarter of 2025.

Geographically, sales growth over the nine months was widespread:

- **Domestic market (Italy): sales of € 544.5 million, up +8.8%** compared to September 30, 2025 (€ 500.4 million).
- **Foreign markets: sales of € 902.9 million, an increase of +11.3%** compared to September 30, 2025 (€ 811.2 million).

Sales Performance of the Two Segments

- **Technical Gases segment:** nine-month sales reached **€ 714.1 million (+7.7%** compared to the first nine months of 2025, of which -0.4 pp from exchange rate effects and +0.9 pp from changes in the consolidation scope). The result reflects the Group's ability to gain market share and win new customers, effectively and promptly managing energy cost fluctuations, even against the backdrop of an industrial recovery that remains gradual and selective.
- **Home Medical Care segment (Vivisol):** confirmed a sustained expansion trajectory, reaching sales of € **764.3 million (+12.6%** compared to the first nine months of 2025, of which -0.1 pp from exchange rate effects and +2.8 pp from changes in the consolidation scope). The favourable trend continues to be driven by the steady increase in treated patients, territorial capillarity, and solid growth across all key therapeutic areas—particularly *sleep apnea* and *advanced nursing care*—as well as the positive contribution from recent acquisitions.

Partnerships and Acquisitions

Since the beginning of the year, the SOL Group has significantly accelerated its strategic development plan both organically and through targeted extraordinary transactions:

- **First half:** finalized the acquisition of 100% of the Italian company Haemopharm Biofluids S.r.l. (peritoneal dialysis fluids), 100% of the Swiss company VitalAire Schweiz AG (home respiratory care), 100% of the British Remeo Group (specialist respiratory care), and 70% of the Brazilian companies Oxigenar and Pulmonair (B2C respiratory care).
- **Third quarter:** the growth path continued with the closing of the acquisition of 51% of the IBG Group, creating a major strategic platform for developing activities in the Brazilian technical gases market, and the acquisition of 100% of the Danish company Nowus Healthcare A/S, a leading provider of respiratory care active in Denmark, Sweden, Norway, Finland, and the United Kingdom.
- **Fourth quarter:** the Group completed the acquisition of 100% of the share capital of the Polish company Wentimed Sp. z o.o., specialized in home mechanical ventilation treatments and palliative care.

Management Commentary

Marco Annoni, Vice-President of SOL S.p.A., stated: *"The results of the first nine months of 2026 confirm the solidity of the SOL Group and the effectiveness of our strategic choices, which combine business diversification, internationalization, and continuous innovation in our service offering. The acceleration recorded in the third quarter, combined with steady expansion in key European and non-European markets, demonstrates the responsiveness and competitive strength of our organization even in an overall economic environment that remains uneven."*

Aldo Fumagalli Romario, Chairman of SOL S.p.A., added: *"We look to the final quarter of the year with confidence and determination, supported by a positive commercial trend in both technical gases and home care. We will continue to closely monitor macroeconomic and geopolitical developments, maximizing the value of recent strategic acquisitions and confirming our objectives of sustainable growth and long-term value creation."*

****

The Manager responsible for preparing the corporate financial reports of SOL S.p.A., Marco Michele Leccese, declares, pursuant to paragraph 2 of Article 154-bis of the Consolidated Law on Finance (Legislative Decree 58/1998), that the accounting information contained in this press release corresponds to the documentary results, books, and accounting records.

SOL is an Italian multinational Group operating in Europe, Turkey, Morocco, Brazil, India, China, Kuwait, Ecuador, and Peru in two distinct main sectors: the production, applied research, and marketing of technical, pure, and medical gases (Technical Gases Division) and Home Medical Care (Home Care Division).

Monza, November 12th, 2026